VRML Vermillion

Vermillion to Present at the Canaccord Medical Technology & Diagnostics Forum

Vermillion to Present at the Canaccord Medical Technology & Diagnostics Forum

AUSTIN, Texas, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer, will present at the upcoming Canaccord Genuity Medical Technologies & Diagnostics Forum being held November 15, 2018 at the Westin Grand Central Hotel, New York, NY.

2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

Date:

Time:

Location:

Thursday, November 15, 2018

3:30 pm Eastern Time

Westin Grand Central Hotel, New York

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases.  The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit .

Investor Relations Contact:

Ashley Robinson

LifeSci Advisors LLC

Tel (617) 535-7742

 

EN
12/11/2018

Underlying

VRMLVermillion

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vermillion

 PRESS RELEASE
Free
VRML VERMILLION

Aspira Women’s Health, Inc. to Present at Cantor Virtual Healthcare ...

Aspira Women’s Health, Inc. to Present at Cantor Virtual Healthcare Conference AUSTIN, Texas, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the 2020 Cantor Virtual Healthcare Conference taking place on September 15-17, 2020. Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer will be available for 1x1 meetings with investors on September 17, 2020.  Conference details are as follows:   Cantor Virtual Healthcare Confe...

September 8, 2020 1 EN
 PRESS RELEASE
Free
VRML VERMILLION

UPDATE – Aspira Women’s Health Reports Second Quarter 2020 Financi...

UPDATE – Aspira Women’s Health Reports Second Quarter 2020 Financial Results Conference Call scheduled for today, August 13th at 4:30 p.m. ET AUSTIN, Texas, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2020. “Despite late first quarter and second quarter challenges from COVID-19, we have delivered strong revenue and volume growth in the first half of 2020 as compared to the first half of 2019. ...

August 14, 2020 1 EN
 PRESS RELEASE
Free
VRML VERMILLION

Aspira Women’s Health Reports Second Quarter 2020 Financial Results

Aspira Women’s Health Reports Second Quarter 2020 Financial Results Conference Call scheduled for today, August 13th at 4:30 p.m. ET AUSTIN, Texas, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“ASPIRA”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the second quarter ended June 30, 2020. “Despite late first quarter and second quarter challenges from COVID-19, we have delivered strong revenue and volume growth in the first half of 2020 as compared to the first half of 2019. In fact, ...

August 13, 2020 1 EN
 PRESS RELEASE
Free
VRML VERMILLION

Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial ...

Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial Results on August 13th AUSTIN, Texas, July 31, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020 after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time. Thursday, August 13th @ 4:30pm ETDomestic:201-689-8472International:877-407-4021Conference ID:13706942Webcast: About Aspira Women’s Health Inc...

July 31, 2020 1 EN
 PRESS RELEASE
Free
VRML VERMILLION

Aspira Women’s Health Inc. Announces Equity Financing of Approximate...

Aspira Women’s Health Inc. Announces Equity Financing of Approximately $11 Million AUSTIN, Texas, July 01, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that investors, including certain affiliates of Jack W. Schuler, ASPIRA’s largest stockholder, have agreed to purchase approximately $11 million of unregistered shares of ASPIRA's common stock in a private placement at a price of $3.50 per share. The closing of the private placement is expected to occur on July 6...

July 1, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch